Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Department of Dermatology, University Medical Center Mainz, Mainz, Germany.
J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1185-1190.e1. doi: 10.1016/j.jaip.2017.10.001. Epub 2017 Nov 8.
Chronic spontaneous urticaria is characterized by fluctuating symptoms. Its activity is assessed with the urticaria activity score (UAS). Two versions of the urticaria activity score used for 7 consecutive days (UAS7) are available: (1) The guideline-recommended UAS7, with once-daily documentation, and (2) the UAS7, with twice-daily documentation.
To better characterize both UAS7 versions with regard to their validity, reliability, sensitivity to change, minimal important difference (MID), and smallest detectable change (SDC).
One hundred thirty adult patients with chronic spontaneous urticaria completed both UAS7 versions, the Patients Global Assessment (PatGA) of disease activity, the Urticaria Control Test (UCT), the Chronic Urticaria Quality of Life Questionnaire, and the Dermatology Life Quality Index before and after the initiation of omalizumab therapy. Physicians completed a Physician Global Assessment of disease activity.
The UAS7 and the UAS7 showed high correlation with the activity anchor PatGA (r = 0.568, P < .001 and r = 0.605, P < .001) and the UCT (r = -0.580, P < .001 and r = -0.585, P < .001). The wheal and pruritus scores of the UAS7 and the UAS7 exhibited respectable internal consistency and, in each UAS7 version, correlated well with each other (Cronbach α = 0.78, r = 0.640, P < .001, and Cronbach α = 0.77, r = 0.626, P < .001). Changes in the UAS7 and UAS7 correlated well with PatGA changes (r = 639, P < .001, and r = .763, P < .001) and with UCT changes (r = -0.642, P < .001, and r = -0.703, P < .001). The MID was 11 for the UAS7 (SDC = 12) and 12 for the UAS7 (SDC = 11).
The UAS7 and UAS7 show good and comparable clinimetric properties, including good sensitivity to change, and similar MIDs.
慢性自发性荨麻疹的特点是症状波动。其活动度采用荨麻疹活动评分（UAS）进行评估。有两种版本的连续 7 天使用的荨麻疹活动评分（UAS7）：（1）推荐使用的 UAS7，每天记录一次，（2）UAS7，每天记录两次。
更好地描述两种 UAS7 版本在有效性、可靠性、对变化的敏感性、最小临床重要差异（MID）和最小可检测变化（SDC）方面的特点。
130 名成年慢性自发性荨麻疹患者在开始奥马珠单抗治疗前后完成了两种 UAS7 版本、患者整体评估（PatGA）疾病活动度、荨麻疹控制测试（UCT）、慢性荨麻疹生活质量问卷和皮肤病生活质量指数。医生完成了疾病活动度的医生整体评估。
UAS7 与活动锚定 PatGA（r = 0.568，P <.001 和 r = 0.605，P <.001）和 UCT（r = -0.580，P <.001 和 r = -0.585，P <.001）高度相关。UAS7 和 UAS7 的风团和瘙痒评分具有良好的内部一致性，并且在每个 UAS7 版本中，彼此之间相关性良好（Cronbach α = 0.78，r = 0.640，P <.001，和 Cronbach α = 0.77，r = 0.626，P <.001）。UAS7 和 UAS7 的变化与 PatGA 的变化（r = 639，P <.001 和 r =.763，P <.001）和 UCT 的变化（r = -0.642，P <.001 和 r = -0.703，P <.001）相关性良好。MID 为 UAS7 的 11（SDC = 12）和 UAS7 的 12（SDC = 11）。
UAS7 和 UAS7 具有良好且可比的临床计量学特性，包括对变化的良好敏感性和相似的 MID。
